Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment

B Shariat-Madar1, D Kolte2, A Verlangieri2, Z Shariat-Madar21College of Literature, Science, and the Arts, University of Michigan, Ann Arbor MI, USA; 2School of Pharmacy, Department of Pharmacology, University of Mississippi, University, MS, USAAbstract: Recently, we serendipitously discovered that...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shariat-Madar Z, Shariat-Madar B, Kolte D, Verlangieri AJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	prolylcarboxypeptidase (PRCP) alpha-melanocyte-stimulating hormone Obesity Plasma kallikrein Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/9b938dab003c40599c17b59fc30f487c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9b938dab003c40599c17b59fc30f487c
record_format	dspace
spelling	oai:doaj.org-article:9b938dab003c40599c17b59fc30f487c2021-12-02T08:55:20ZProlylcarboxypeptidase (PRCP) as a new target for obesity treatment1178-7007https://doaj.org/article/9b938dab003c40599c17b59fc30f487c2010-04-01T00:00:00Zhttps://www.dovepress.com/prolylcarboxypeptidase-prcp-as-a-new-target-for-obesity-treatment-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007B Shariat-Madar1, D Kolte2, A Verlangieri2, Z Shariat-Madar21College of Literature, Science, and the Arts, University of Michigan, Ann Arbor MI, USA; 2School of Pharmacy, Department of Pharmacology, University of Mississippi, University, MS, USAAbstract: Recently, we serendipitously discovered that mice with the deficiency of the enzyme prolylcarboxypeptidase (PRCP) have elevated α-melanocyte-stimulating hormone (α-MSH) levels which lead to decreased food intake and weight loss. This suggests that PRCP is an endogenous inactivator of α-MSH and an appetite stimulant. Since a modest weight loss can have the most profound influence on reducing cardiovascular risk factors, the inhibitors of PRCP would be emerging as a possible alternative for pharmacotherapy in high-risk patients with obesity and obesity-related disorders. The discovery of a new biological activity of PRCP in the PRCP-deficient mice and studies of α-MSH function indicate the importance and complexity of the hypothalamic pro-opiomelanocortin (POMC) system in altering food intake. Identifying a role for PRCP in regulating α-MSH in the brain may be a critical step in enhancing our understanding of how the brain controls food intake and body weight. In light of recent findings, the potential role of PRCP in regulating fuel homeostasis is critically evaluated. Further studies of the role of PRCP in obesity are much needed.Keywords: prolylcarboxypeptidase, melanocyte-stimulating harmone, appetite, weight loss, cardiovascular risk, obesityShariat-Madar ZShariat-Madar BKolte DVerlangieri AJShariat-Madar ZDove Medical Pressarticleprolylcarboxypeptidase (PRCP)alpha-melanocyte-stimulating hormone Obesity Plasma kallikreinSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 67-78 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	prolylcarboxypeptidase (PRCP) alpha-melanocyte-stimulating hormone Obesity Plasma kallikrein Specialties of internal medicine RC581-951
spellingShingle	prolylcarboxypeptidase (PRCP) alpha-melanocyte-stimulating hormone Obesity Plasma kallikrein Specialties of internal medicine RC581-951 Shariat-Madar Z Shariat-Madar B Kolte D Verlangieri AJ Shariat-Madar Z Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
description	B Shariat-Madar1, D Kolte2, A Verlangieri2, Z Shariat-Madar21College of Literature, Science, and the Arts, University of Michigan, Ann Arbor MI, USA; 2School of Pharmacy, Department of Pharmacology, University of Mississippi, University, MS, USAAbstract: Recently, we serendipitously discovered that mice with the deficiency of the enzyme prolylcarboxypeptidase (PRCP) have elevated α-melanocyte-stimulating hormone (α-MSH) levels which lead to decreased food intake and weight loss. This suggests that PRCP is an endogenous inactivator of α-MSH and an appetite stimulant. Since a modest weight loss can have the most profound influence on reducing cardiovascular risk factors, the inhibitors of PRCP would be emerging as a possible alternative for pharmacotherapy in high-risk patients with obesity and obesity-related disorders. The discovery of a new biological activity of PRCP in the PRCP-deficient mice and studies of α-MSH function indicate the importance and complexity of the hypothalamic pro-opiomelanocortin (POMC) system in altering food intake. Identifying a role for PRCP in regulating α-MSH in the brain may be a critical step in enhancing our understanding of how the brain controls food intake and body weight. In light of recent findings, the potential role of PRCP in regulating fuel homeostasis is critically evaluated. Further studies of the role of PRCP in obesity are much needed.Keywords: prolylcarboxypeptidase, melanocyte-stimulating harmone, appetite, weight loss, cardiovascular risk, obesity
format	article
author	Shariat-Madar Z Shariat-Madar B Kolte D Verlangieri AJ Shariat-Madar Z
author_facet	Shariat-Madar Z Shariat-Madar B Kolte D Verlangieri AJ Shariat-Madar Z
author_sort	Shariat-Madar Z
title	Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
title_short	Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
title_full	Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
title_fullStr	Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
title_full_unstemmed	Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
title_sort	prolylcarboxypeptidase (prcp) as a new target for obesity treatment
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/9b938dab003c40599c17b59fc30f487c
work_keys_str_mv	AT shariatmadarz prolylcarboxypeptidaseprcpasanewtargetforobesitytreatment AT shariatmadarb prolylcarboxypeptidaseprcpasanewtargetforobesitytreatment AT kolted prolylcarboxypeptidaseprcpasanewtargetforobesitytreatment AT verlangieriaj prolylcarboxypeptidaseprcpasanewtargetforobesitytreatment AT shariatmadarz prolylcarboxypeptidaseprcpasanewtargetforobesitytreatment
_version_	1718398320096837632

Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment

Ejemplares similares